QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 发表日期：2022     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review 期刊论文 TRANSLATIONAL CANCER RESEARCH, 2022 作者:  He, Libin;  Shen, Xiabo;  Liu, Yiyuan;  Gao, Lu;  Wu, Jiayi 收藏  |  浏览/下载：22/0  |  提交时间：2022/12/23 Advanced human epidermal growth factor receptor 2-positive breast cancer (advanced HER2-positive breast cancer)  apatinib  case report   A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer 期刊论文 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 卷号: 14 作者:  Yan, Min;  Yuan, Peng;  Ouyang, Quchang;  Cheng, Ying;  Han, Guohui 收藏  |  浏览/下载：27/0  |  提交时间：2022/12/23 breast cancer  chemotherapy  efficacy  lobaplatin  neoplasm metastasis  safety   Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China 期刊论文 THORACIC CANCER, 2022 作者:  Xu, Chunwei;  Si, Lu;  Wang, Wenxian;  Li, Ziming;  Song, Zhengbo 收藏  |  浏览/下载：36/0  |  提交时间：2022/12/22 fusion  precision medicine  solid tumor  targeted therapy  tyrosine receptor kinase   Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40 作者:  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Fang, Zi-Ru;  Li, Guang-Liang 收藏  |  浏览/下载：14/0  |  提交时间：2022/12/23 Platelet-to-Lymphocyte ratio (PLR) as a predictive marker in HER2 positive metastatic breast cancer patients treated with first-line trastuzumab therapy. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40 作者:  Fang, Zi-Ru;  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Shao, Xi-Ying 收藏  |  浏览/下载：11/0  |  提交时间：2022/12/23